Cancer Supportive Care Market Forecast Projections to 2022 on a Globa March 2017

New analysis on Cancer Supportive Care Market: Patent Expirations Create Opportunities for Biosimilar in the Chemotherapy Induced Anemia and Neutropenia Markets, 2017 added in Order report by calling ReportsnReports.com at [phone] OR send an email on [email protected] with Cancer Supportive Care Industry in subject line and your contact details. Complete Report on Sports Medicine Market is Available at http://www.reportsnreports.com/reports/974418-global-cancer-supportive-care- therapeutics-market-to-2022-patent-expirations-create-opportunities-for-biosimilars-in-the- chemotherapy-induced-anemia-and-neutropenia-markets.html . The report “Cancer Supportive Care Market: Patent Expirations Create Opportunities for Biosimilar in the Chemotherapy Induced Anemia and Neutropenia Markets, 2017” analysis six key indications which are chemotherapy-induced neutropenia (CIN), chemotherapy- induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV), cancer pain, bone metastasis and oral mucositis. These indications are not only distressing for patients, but can also lead to treatment cessation, which in turn increases patient mortality. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs will rise. The cancer supportive care market report analyzes products in terms of market value (US$ Mn), by drug class, disease indication, region, and distribution channels, and provides information regarding regional market dynamics, regulations, competitive landscape, current trends, market estimations, clinical trials and forecast. Key market participants covered in the cancer supportive care market report include Amgen, Bayer, Heron, INSYS, Kyowa Hakko Kirin, Daiichi Sankyo, Spectrum, Depomed, Johnson & Johnson, Eisai, Ono , Teva, Eli Lilly, Tesaro, Otsuka, Roche, Pfizer, Merck & Co., Shionogi, Orion, GW Pharmaceuticals, Almirall. The report Cancer Supportive Care Market- Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets, 2017 provides an introduction to key indications within cancer supportive care, including disease epidemiology, symptoms, pathophysiology, diagnosis and disease staging and prognosis. The global cancer supportive care market is forecast to experience a low level of growth, with revenue increasing from USD11.7 Billion in 2015 to USD12.4 Billion in 2022 at a compound annual growth rate (CAGR) of 1.08%. The unmet need’s within the cancer supportive care therapy area varies between indications. CIN and CINV both already have treatment regimens that can significantly decrease the incidence rate. However, the level of unmet need for CIA, cancer pain, oral mucositis and bone metastasis is high, with treatment focusing heavily on alleviating the symptoms instead of treating the underlying cause.